Richard A Young bought stock once, on Aug 3, 2026

Richard A. Young, Ph.D. is a scientific founder and director of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) and serves as a director of the company, where he has recently reported insider trades in his capacity as a board member.( A molecular biologist by training, he is also a Professor of Biology at the Massachusetts Institute of Technology and a Member of the Whitehead Institute for Biomedical Research, focusing on gene regulatory circuitry in health and disease.( In addition to Syros, Dr. Young has founded or co‑founded several biotechnology companies, including CAMP4 Therapeutics, Dewpoint Therapeutics, Omega Therapeutics, and Paratus Sciences, and has served on boards or advisory roles across the life sciences sector.(

Dr. Young’s career is marked by seminal contributions to genome-wide analysis technologies and the elucidation of transcriptional and epigenetic regulatory mechanisms, particularly in embryonic stem cells and cancer.( He holds a B.S. in Biological Sciences from Indiana University and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University, followed by postdoctoral research at Stanford University.( Recognized as one of Scientific American’s top 50 leaders in science, technology and business, he is an elected member of the National Academy of Sciences and the National Academy of Medicine, and has advised organizations such as Science magazine, the National Institutes of Health, and the World Health Organization.(

Written by Perplexity from public sources.